NCT00841516View on ClinicalTrials.gov

Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

May 31, 2013

Conditions
Allergic Rhinoconjunctivitis
Interventions
OTHER

Placebo

Placebo was given the same way as a subcutaneous (just under the skin) injection.

BIOLOGICAL

rBet v1-FV

Placebo was given the same way as a subcutaneous (just under the skin) injection.

Trial Locations (1)

41345

Prof. Dr. med. Sabina Rak, Gothenburg

All Listed Sponsors
lead

Allergopharma GmbH & Co. KG

INDUSTRY

NCT00841516 - Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative | Biotech Hunter | Biotech Hunter